|
Market Closed -
Euronext Paris
11:55:00 2026-09-18 am EDT
|
5-day change | 1st Jan Change | ||
| 74.05 EUR | -1.61% |
|
+1.08% | -10.48% |
| Sep. 18 | Sanofi's Rabies Vaccine VaxRabeo Recommended for EU Approval | MT |
| Sep. 17 | Sanofi : UBS reiterates its Neutral rating | ZD |
| Market Cap | 88.72B 102B 83.77B 76.07B 143B 9,762B 143B 1,003B 387B 4,963B 382B 374B 15,970B | P/E 2026 * |
11.8x | P/E 2027 * | 10.3x |
|---|---|---|---|---|---|
| Enterprise Value | 100B 115B 94.59B 85.9B 161B 11,024B 162B 1,133B 437B 5,605B 432B 422B 18,034B | EV / Sales 2026 * |
2.1x | EV / Sales 2027 * | 1.92x |
| Free-Float |
88.34% | Yield 2026 * |
5.74% | Yield 2027 * | 6.07% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| SAN | Real-time | |
CBOE
| SAN | Real-time | |
|
London S.E.
| 0O59 | Delayed | |
|
Tradegate
| SNW | Real-time | |
|
Boerse Muenchen
| SNW | Real-time | |
|
Deutsche Boerse AG
| SNW | Delayed | |
|
Xetra
| SNW | Delayed | |
|
Börse Stuttgart
| SNW | Delayed | |
|
Borsa Italiana
| 1SAN | End-of-day quote | |
|
OTC Markets
| SNYNF | Delayed | |
|
Mexican S.E.
| SAN1 N | End-of-day quote | |
|
Bulgaria S.E.
| SNW | End-of-day quote | |
|
Swiss Exchange
| SAN | Delayed | |
|
Wiener Boerse
| SANO | End-of-day quote | |
|
CBOE
| 0O59 | Real-time |
Last Transcript: Sanofi
| 1 day | -1.61% | ||
| 1 week | +1.08% | ||
| Current month | -3.59% | ||
| 1 month | -4.66% | ||
| 3 months | +0.97% | ||
| 6 months | -2.72% | ||
| Current year | -10.48% |
| 1 week | 73.45 |  | 75.96 |
| 1 month | 73.22 | | 79.36 |
| Current year | 71.25 | | 84.97 |
| 1 year | 71.25 | | 91.15 |
| 3 years | 71.25 | | 110.88 |
| 5 years | 71.25 | | 110.88 |
| 10 years | 62.88 | | 110.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 2026-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 57 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 65 | 2020-04-27 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/20/26 | Buy | Chief Executive Officer | 1,506 | 0.0001% | ||
| 8/20/26 | Buy | Head of Human Resources | 54 | 0.0000% | ||
| 8/20/26 | Buy | Executive/Senior Manager | 840 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.61% | +1.08% | -7.61% | -27.17% | 102B | |
| +0.04% | +3.34% | +51.12% | +101.82% | 1,028B | |
| -0.09% | +1.66% | +55.02% | +66.18% | 651B | |
| -0.02% | +2.66% | +18.91% | +71.47% | 466B | |
| -1.22% | +3.66% | +36.44% | +38.32% | 346B | |
| -0.79% | +2.73% | +19.03% | +25.08% | 266B | |
| +0.58% | +6.76% | +11.13% | +16.52% | 259B | |
| +1.55% | +2.20% | +39.81% | +46.55% | 208B | |
| +0.79% | +1.84% | -28.27% | -56.71% | 191B | |
| -0.52% | +4.45% | +32.12% | +98.51% | 186B | |
| Average | +0.02% | +3.04% | +22.77% | +38.06% | 370.35B | |
| Weighted average by Cap. | +0.18% | +3.04% | +33.97% | +59.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.65B 54.64B 44.99B 40.86B 76.55B 5,243B 76.87B 539B 208B 2,666B 205B 201B 8,577B | 50.64B 58.08B 47.82B 43.42B 81.36B 5,573B 81.7B 573B 221B 2,833B 218B 213B 9,117B |
| Net income | 7.48B 8.58B 7.06B 6.41B 12.01B 823B 12.06B 84.59B 32.64B 418B 32.22B 31.5B 1,346B | 8.89B 10.19B 8.39B 7.62B 14.28B 978B 14.33B 101B 38.78B 497B 38.28B 37.43B 1,600B |
| Net Debt | 11.46B 13.15B 10.82B 9.83B 18.42B 1,261B 18.49B 130B 50.03B 641B 49.38B 48.29B 2,064B | 8.34B 9.56B 7.87B 7.15B 13.39B 917B 13.45B 94.28B 36.38B 466B 35.91B 35.11B 1,501B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | €74.05 | -1.61% | 5,306,026 |
| 26-09-17 | €75.26 | +1.22% | 1,782,873 |
| 26-09-16 | €74.35 | +0.19% | 2,267,684 |
| 26-09-15 | €74.21 | -1.62% | 1,854,494 |
| 26-09-14 | €75.43 | +2.96% | 2,765,071 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
Select your edition
All financial news and data tailored to specific country editions
